Daniel G. Remick, MD

Professor of Pathology & Laboratory Medicine

Contact Information

Email – remickd@bu.edu
Phone – 617 414-7043

Degree(s) –

University of Minnesota – Duluth, MN BS 1975-78 Chemistry
Mayo Medical School – Rochester, MN MD 1978-82 Medicine
University of Michigan – Ann Arbor, MI Resident 1982-84 Anatomic Pathology
University of Michigan – Ann Arbor, MI Fellowship 1984-86 Anatomic Pathology

Positions and Employment

1975 Honorable Discharge U.S. Air Force. Rank – Sergeant, Specialty – Romanian Translator
1978 Graduate Summa Cum Laude from Univ. Minnesota – Duluth
1986-1988 Instructor, Department of Pathology, Univ. Michigan Medical School
1987- Director, Autopsy Service, Univ. Michigan Medical School
1988-1992 Assistant Professor of Pathology, Univ. Michigan Medical School
1992-1998 Associate Professor of Pathology, Univ. Michigan Medical School
1994-2002 Director, Electron Microscopy Service, Univ. Michigan Medical School
1998-2006 Professor of Pathology, Univ. Michigan Medical School
2002-2006 Assistant Dean of Admissions, U of Michigan Medical School
9/2006-
present
Professor, Department of Pathology & Laboratory Medicine, Boston University School of Medicine
9/2006-
8/31/2019
Chair, Department of Pathology & Laboratory Medicine, Boston University School of Medicine

Professional Experience

1997 – 2001 Past Chair, Michigan Association of Medical Examiners
1997 – 2000 Past Chair, Advisory Committee on Appointments, Promotions and Tenure.
1998 – 2001 Past Chair, University Committee on Use and Care of Animals, U of Michigan
1998 – 2003 Committees: NIH Surgery, Anesthesiology and Trauma Study Section
1999 2001 Associate Editor, Journal of Immunology
2001 – 2003 Chair, NIH SAT study section
2001,2,3,4,5,6 Chair, Multiple Special Emphasis Panels, NIH
2001 – Present Editorial board, Journal of Investigative Surgery
2002 – Present Associate Editor, Shock

Fellowships and Awards

2006 American Red Cross Certificate of Appreciation for Extraordinary Personal Action
2006 Mentor – Marcin Osuchowski, recipient of the Shock Society’s Young Investigator Award
2008 Distinguished Service Award, Shock Society
2009 Mentor for Florin Craciun, graduate student, recipient of Shock Society’s Travel Award
2009 Selected by the BUSM class of 2012 to serve on the Appeals Committee for Academic Promotion
2009 President, Shock Society
2010 Mentor for Bryan Belikoff, MDPhD student, Travel Award from American Society of Investigative Pathology
2010 Presented 8th Annual John Spitzer Distinguished Lecture, Louisiana State University Health Sciences Center, March 25. Sepsis Complex Inflammation for a Complex Disease
2010 – 2013 Chair, Advocacy Committee, Association of Pathology Chairs
2010 – 2013 Elected to Council, Association of Pathology Chairs
2011 – 2014 Elected to Council, Society for Leukocyte Biology
2011 – 2014 Elected to Council, American Society of Investigative Pathology
2011 Mentor for Jacqueline Bouchard, graduate student, recipient of ASIP travel award

Research interests

The laboratory focuses on investigating the inflammatory response with particular emphasis on cytokines. We are attempting to determine how the inflammatory response results in tissue/organ injury and death. To achieve this goal the laboratory uses a variety of methods ranging from whole animal models to isolated cells with reporter gene constructs. The ultimate focus of the lab is to understand the reaction to inflammation so that it may be modulated to improve health outcomes. It should be specifically noted that the modulation may include either blocking excessive inflammation or augmenting immunosuppression. Common themes: The primary theme which ties together all of the projects is the careful measurement of cytokines. Cytokines are peptide mediators of the inflammatory response which represent critical components. They have been successfully modulated to improve health in patients with severe diseases. There are several discrete projects within the laboratory.
Sepsis. Sepsis represents the host response to severe infections and results in substantial morbidity and mortality. The mortality for a septic patient  exceeds 30% even in the best care situations. It is also important to note that the mortality for sepsis is calculated on the basis of 28 days survival, rather than the typical five-year survival used for cancer patients. Consequently, the number of years of life lost with sepsis is substantial. Our laboratory attempts to decipher the mechanisms for sepsis induced organ injury and mortality. The studies use a combination of a cell based approaches, whole animal experiments, and exploration of biomarker profiles in patients. Previous work has demonstrated that patients who suffer traumatic injury are at markedly increased risk for the development of sepsis, and its subsequent mortality. We are collecting plasma from patients who suffered a severe traumatic injury in a longitudinal fashion in order to determine if there is a biomarker profile which predicts both the development of sepsis, and that the outcome once a patient becomes a septic.

Asthma. Asthma represents another significant inflammatory condition with tremendous annual

health-care costs. Our laboratory has developed a novel model of asthma like a pulmonary inflammation. Among children in inner cities, the major allergen which induces asthma comes from cockroaches rather than dog or cat allergens, or pollen. We collected dust from the homes were children had asthma and used this to induce inflammation in a mouse. the model was remarkably robust and produced several of the features observed in patients with asthma including the pulmonary recruitment of eosinophils, neutrophils, as well as mucous hyperplasia, and airways hyperreactivity. We have begun to use this model to explore novel treatments for asthma. Tumor necrosis factor (TNF) is a poorly named inflammatory mediator which actually has little to do with the necrosis of tumors. However, it is an important regulator of many aspects of chronic inflammation. Inhibitors of TNF have been used for years in the treatment of chronic inflammatory conditions such as rheumatoid arthritis. We were one of the first labs to demonstrate that blocking the biological activity of TNF could improve asthma. Panel A in the figure shows a lung from an animal which has been treated with an antibody directed against TNF. This is essentially normal histology with very little inflammation. In contrast, panel B shows an animal which received a control antibody. There are several dark purple dots surrounding the blood vessels and airways. These purple areas represent the nuclei of the inflammatory cells which have been elicited as part of the asthmatic response.


Remick Lab Members

  • John Kim, Ph.D., Research Assistant Professor
  • Elizabeth Duffy, M.A., Assistant Professor



Recent publications:

  1. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V: Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a ‘melphalan recall’ reaction, Bone Marrow Transplant 2010, 45:21-24, PMID: 19421171
  2. Horton DL, Remick DG: Delayed addition of glucocorticoids selectively suppresses cytokine production in stimulated human whole blood, Clin Vaccine Immunol 2010, 17:979-985 PMID: 20445007
  3. Draganov D, Teiber J, Watson C, Bisgaier C, Nemzek J, Remick D, Standiford T, La Du B: PON1 and Oxidative Stress in Human Sepsis and an Animal Model of Sepsis, Adv Exp Med Biol 2010, 660:89-97, PMID: 20221873
  4. Zhou B, Xu W, Herndon D, Tompkins R, Davis R, Xiao W, Wong WH, Toner M, Warren HS, Schoenfeld DA, Rahme L, McDonald-Smith GP, Hayden D, Mason P, Fagan S, Yu YM, Cobb JP, Remick DG, Mannick JA, Lederer JA, Gamelli RL, Silver GM, West MA, Shapiro MB, Smith R, Camp DG, 2nd, Qian W, Storey J, Mindrinos M, Tibshirani R, Lowry S, Calvano S, Chaudry I, Cohen M, Moore EE, Johnson J, Moldawer LL, Baker HV, Efron PA, Balis UG, Billiar TR, Ochoa JB, Sperry JL, Miller-Graziano CL, De AK, Bankey PE, Finnerty CC, Jeschke MG, Minei JP, Arnoldo BD, Hunt JL, Horton J, Brownstein B, Freeman B, Maier RV, Nathens AB, Cuschieri J, Gibran N, Klein M, O’Keefe G: Analysis of factorial time-course microarrays with application to a clinical study of burn injury, Proc Natl Acad Sci U S A 2010, 107:9923-9928, PMID: 20479259
  5. Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O’Keefe G, Sperry J, Remick D, Tompkins R, Maier RV: Early Elevation in Random Plasma Il-6 after Severe Injury Is Associated with Development of Organ Failure, Shock 2010, 34:346-351, PMID: 20844410
  6. Natarajan S, Kim J, Remick DG: Chronic pulmonary LPS tolerance induces selective immunosuppression while maintaining the neutrophilic response, Shock 2010, 33:162-169, PMID: 19487981
  7. Osuchowski MF, Craciun FL, Schuller E, Sima C, Gyurko R, Remick DG: Untreated type 1 diabetes increases sepsis-induced mortality without inducing a prelethal cytokine response, Shock 2010, 34:369-376, PMID: 20610941
  8. Uddin J, Gonzalez AE, Gilman RH, Thomas LH, Rodriguez S, Evans CA, Remick DG, Garcia HH, Friedland JS: Mechanisms regulating monocyte CXCL8 secretion in neurocysticercosis and the effect of antiparasitic therapy, J Immunol 2010, 185:4478-4484, PMID: 20826750
  9. Vaickus LJ, Bouchard J, Kim J, Natarajan S, Remick DG: Assessing pulmonary pathology by detailed examination of respiratory function, Am J Pathol 2010, 177:1861-1869, PMID: 20724595
  10. Vaickus LJ, Bouchard J, Kim J, Natarajan S, Remick DG: Oral Tolerance Inhibits Pulmonary Eosinophilia in a Cockroach Allergen Induced Model of Asthma: A Randomized Laboratory Study, Respir Res 2010, 11:160, PMID: 21092270
  11. Craciun FL, Schuller ER, Remick DG: Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival, J Immunol 2010, 185:6930-6938, PMID: 21041722
  12. Vaickus LJ, Bouchard J, Kim J, Natarajan S, Remick DG: Inbred and outbred mice have equivalent variability in a cockroach allergen-induced model of asthma, Comp Med 2010, 60:420-426, PMID: 21262127
  13. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG: The Pathogenesis of Sepsis, Annu Rev Pathol 2011, 6:19-48, PMID: 20887193
  14. Natarajan S, Kim J, Bouchard J, Cruikshank W, Remick DG: Reducing LPS content in cockroach allergens increases pulmonary cytokine production without increasing inflammation: A randomized laboratory study, BMC Pulm Med 2011, 11:12, PMID: 21345191
  15. Belikoff BG, Hatfield S, Georgiev P, Ohta A, Lukashev D, Buras JA, Remick DG, Sitkovsky M: A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice, J Immunol 2011, 186:2444-2453, PMID: 21242513
  16. Belikoff B, Hatfield S, Sitkovsky M, Remick DG: Adenosine Negative Feedback on A2A Adenosine Receptors Mediates Hyporesponsiveness in Chronically Septic Mice, Shock 2011, 35:382-387, PMID: 21192284
  17. Kim J, Natarajan S, Bae H, Jung SK, Cruikshank W, Remick DG: Herbal medicine treatment reduces inflammation in a murine model of cockroach allergen-induced asthma, Ann Allergy Asthma Immunol 2011, 107:154-162, PMID: 21802024
  18. Kong X, Thimmulappa R, Craciun F, Harvey C, Singh A, Kombairaju P, Reddy SP, Remick D, Biswal S: Enhancing Nrf2 Pathway by Disruption of Keap1 in Myeloid Leukocytes Protects Against Sepsis, Am J Respir Crit Care Med 2011, PMID: 21799073
  19. Asimaki A, Tandri H, Duffy ER, Winterfield JR, Mackey-Bojack S, Picken MM, Cooper LT, Wilber DJ, Marcus FI, Basso C, Thiene G, Tsatsopoulou A, Protonotarios N, Stevenson WG, McKenna WJ, Gautam S, Remick DG, Calkins H, Saffitz JE: Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy, Circ Arrhythm Electrophysiol 2011, 4:743-752, PMID: 21859801
  20. Kim J, Natarajan S, Vaickus LJ, Bouchard JC, Beal D, Cruikshank WW, Remick DG: Diesel exhaust particulates exacerbate asthma-like inflammation by increasing CXC chemokines, Am J Pathol 2011, 179:2730-2739, PMID: 21967814
  21. Chiswick EL, Duffy E, Japp B, Remick D: Detection and quantification of cytokines and other biomarkers, Methods Mol Biol 2012, 844:15-30, PMID: 22262432
  22. Moitra R, Beal DR, Belikoff BG, Remick DG: Presence of preexisting antibodies mediates survival in sepsis, Shock 2012, 37:56-62, PMID: 21921828
  23. Natarajan S, Kim J, Bouchard J, Cruikshank W, Remick DG: Pulmonary Endotoxin Tolerance Protects against Cockroach Allergen-Induced Asthma-Like Inflammation in a Mouse Model, Int Arch Allergy Immunol 2012, 158:120-130, PMID: 22269653
  24. Winfield RD, Delano MJ, Cuenca AG, Cendan JC, Lottenberg L, Efron PA, Maier RV, Remick DG, Moldawer LL, Cuschieri J: Obese Patients Show a Depressed Cytokine Profile Following Severe Blunt Injury, Shock 2012, PMID: 22266966

 

ACTIVE GRANTS

 

R01 GM82962-01A2 (Remick, PI)                  4/01/2009 – 3/31/2014            1.8 calendar months

NIH/NIGMS                                                                              $250,000

Role of Cytokines in Sepsis and Trauma

The major goals of this grant are to define the immunological alterations in sepsis that lead to multi-organ injury and death, to define treatments which may be more effective.

 

R01 GM 97320 (Remick, contact PI) 09/11/2011 – 08/31/2016                     1.8 calendar months.

NIH/NIGMS                                                                  $250,000

Title: Adenosine and Oxygen Modulate Antimicrobial Defenses

This grant explores the role of extracellular oxygen and adenosine in phagocytic cell function during sepsis.

 

T32 GM86308 (Remick, PI)                07/01/2010 – 06/30/2015

Immunobiology of Trauma

The grant will provide 2 years of training for 2 physician scientists each year.

 

RECENT GRANTS:

R01 ES0113538-01 (Remick, PI)       09/01/06 – 08/31/11                1.2 calendar

NIH/NIEHS                                                                               $304,945

Endotoxin, Allergens and Pollutants in Asthma

The major goals of this grant are to explore the inflammatory response to a novel model of murine asthma like pulmonary inflammation.

 

5 R01 GM050401 (Remick, PI)                       12/01/05 – 11/30/10    2.40 calendar

NIH/NIGMS                                                                              $225,000

Regulation of Ongoing Inflammation

The major goals of this project are to decipher the molecular pathways regulating ongoing inflammation.